Please wait a minute...
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2009, Vol. 10 Issue (1): 7-13    DOI: 10.1631/jzus.B0820178
Biomedicine     
Cationic liposome-mediated transfection of CD40 ligand gene inhibits hepatic tumor growth of hepatocellular carcinoma in mice
Yong-fang JIANG, Jing MA, Yan HE, Yong-hong ZHANG, Yun XU, Guo-zhong GONG
Center for Liver Diseases, the Second Xiangya Hospital, Central South University, Changsha 410011, China
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Objective: To evaluate the efficacy of cationic liposome-mediated CD40 ligand (CD40L) gene therapy for hepatocellular carcinoma. Methods: 1×106 of parental H22 cells or H22 cells transfected with the expression vector containing murine CD40L cDNA encoding the entire coding region (pcDNA3.1+-mCD40L) were inoculated subcutaneously into the left flanks of syngenic BALB/C mice. The tumor-bearing mice (tumor nodules 10 mm in maximal diameter) received the treatment of the intratumoral injection of pcDNA3.1+-mCD40L/Transfectam, pcDNA3.1+, or phosphate-buffered saline (PBS), or no treatment. The mice were monitored for tumor growth weekly. We examined mCD40L messenger ribonucleic acid (mRNA) expression by reverse transcription polymerase chain reaction (RT-PCR) and the histologic changes in tumors at two weeks after intratumoral injection using immunohistochemical staining of tumor tissues. Results: All mice inoculated with parental H22 cells developed a tumor subcutaneously, and the tumor size increased progressively within three weeks. However, the mice receiving H22-CD40L cells exhibited complete regression of the tumor two weeks after tumor cell inoculation. The tumor-bearing animals with the treatment of pcDNA3.1+ or PBS, or without treatment had progressive tumor growth, while those mice treated with pcDNA3.1+-mCD40L exhibited a significant inhibition of tumor growth. RT-PCR analysis showed that 783-bp fragments corresponding to the mCD40L mRNA were amplified only from pcDNA3.1+-mCD40L treated tumors. The tumor samples from pcDNA3.1+-mCD40L-treated mice showed significant lymphocyte infiltration, apoptotic bodies, and confluent necrosis in the tumor tissues. Conclusion: The tumorigenicity of CD40L-expressing cells was abrogated when the cells were implanted subcutaneously. In vivo gene therapy of established liver tumor nodules in mice by the intratumoral injection of pcDNA3.1+-mCD40L led to significant tumor inhibition. There was mCD40L mRNA expression in the tissues from pcDNA3.1+-mCD40L-treated tumors. The intratumoral injection of pcDNA3.1+-mCD40L induced a strong inflammatory, mainly lymphocytic infiltration of the tumor, and increased the necrotic rate of the neoplastic cells.

Key wordsCD40 ligand gene      Hepatocellular carcinoma (HCC)      Cationic liposome      Transfection     
Received: 29 May 2008     
CLC:  R735.7  
Cite this article:

Yong-fang JIANG, Jing MA, Yan HE, Yong-hong ZHANG, Yun XU, Guo-zhong GONG. Cationic liposome-mediated transfection of CD40 ligand gene inhibits hepatic tumor growth of hepatocellular carcinoma in mice. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2009, 10(1): 7-13.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.B0820178     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2009/V10/I1/7

[1] Zhong-dong Wang, Fan-yong Qu, Yuan-yuan Chen, Zhang-shen Ran, Hai-yan Liu, Hai-dong Zhang. Involvement of microRNA-718, a new regulator of EGR3, in regulation of malignant phenotype of HCC cells[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2017, 18(1): 27-36.
[2] Qing-guo Lai, Shao-long Sun, Xiao-hong Zhou, Chen-ping Zhang, Kui-feng Yuan, Zhong-jun Yang, Sheng-lei Luo, Xiao-peng Tang, Jiang-bo Ci. Adipose-derived stem cells transfected with pEGFP-OSX enhance bone formation during distraction osteogenesis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2014, 15(5): 482-490.
[3] WU Xiao-mo, FU Jing-geng, GE Wang-zhong, ZHU Jiang-yan, WANG Jun-yong, ZHANG Wei, QIAN Wei, HUO Ke-ke. Screen p53 mutations in hepatocellular carcinoma by FASAY: A novel splicing mutation[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2007, 8(2): 81-87.